Testing SYS6010 vs Chemotherapy for Advanced Esophageal Cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study compares a new drug called SYS6010 with standard chemotherapy for advanced esophageal squamous cell carcinoma that has progressed after prior treatment. It may be an option if you have this specific type of esophageal cancer and are looking for a new treatment approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of esophageal cancer called squamous cell carcinoma that cannot be removed with surgery or has spread to other parts of the body.
- Your cancer has gotten worse or you had severe side effects after at least one prior cancer treatment (like chemotherapy).
- You are physically active enough that you can take care of yourself (ECOG score 0 or 1).
- Your major organs (like liver, kidneys, bone marrow) work adequately based on blood tests.
- You have at least one tumor that can be measured on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (SYS6010, enlonstobart, and chemotherapy) as a first treatment for people with advanced esophageal cancer that has not spread elsewhere. It aims to find a more effective option for patients who have not received prior therapy for their advanced disease.
This trial tests a new drug called SYS6010 against standard chemotherapy in people with advanced breast cancer that has a specific protein (EGFR) but not the HER2 protein. It is for those whose cancer has come back or spread and who have already had some chemotherapy.
This trial tests a new drug, QLC5508, against standard chemotherapy for people with advanced esophageal cancer that has already been treated. It aims to see if the new drug works better.
This trial tests a new drug called SYS6010 compared to standard chemotherapy for people with EGFR-mutated lung cancer that has stopped responding to pill treatments. It may offer a new option if your current EGFR TKI is no longer working.
This trial tests a new drug called SYS6002 against standard chemotherapy for cervical cancer that has come back or spread. It aims to see if SYS6002 works better for people who have already tried platinum chemo and immunotherapy.
This trial tests a new drug called YL201 against standard chemotherapy for people with advanced esophageal squamous cell carcinoma that has gotten worse after one prior treatment. The goal is to see if YL201 works better at controlling the cancer.
Hear when a new Locally Advanced/Metastatic/Recurrent ESCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.